A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM].

Trial Profile

A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM].

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2013

At a glance

  • Drugs Dalteparin sodium (Primary) ; Gemcitabine (Primary)
  • Indications Pulmonary embolism; Venous thromboembolism
  • Focus Biomarker; Therapeutic Use
  • Acronyms FRAGEM
  • Most Recent Events

    • 17 Nov 2011 Results published in the European Journal of Cancer.
    • 09 Apr 2010 Results from a substudy that investigated the effects of treatment on circulating-tissue factor antigen levels published in Blood Coagulation and Fibrinolysis
    • 20 Sep 2009 Results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top